These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32974448)

  • 1. Use of potassium-binder patiromer for up-titration of renin-angiotensin-aldosterone system inhibition therapy in a patient with chronic heart failure and reduced ejection fraction followed in a multidisciplinary integrated chronic care management programme: a case report.
    Jiménez-Marrero S; Enjuanes C; Yun S; Comín-Colet J
    Eur Heart J Case Rep; 2020 Aug; 4(4):1-4. PubMed ID: 32974448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience of a Bespoke Hyperkalaemia Clinic to Facilitate Prescribing of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction.
    Ali I; Green D; Kalra P; Kalra PA
    Cardiorenal Med; 2022; 12(5-6):196-204. PubMed ID: 36044877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to Improve Adherence to Life-saving Heart Failure Treatments with Potassium Binders.
    Lainscak M
    Card Fail Rev; 2017 Apr; 3(1):33-39. PubMed ID: 28785473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013165. PubMed ID: 32588430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In pursuit of balance: renin-angiotensin-aldosterone system inhibitors and hyperkalaemia treatment.
    Sciatti E; D'Elia E; Balestrieri G; D'Isa S; Iacovoni A; Senni M
    Eur Heart J Suppl; 2023 May; 25(Suppl C):C301-C305. PubMed ID: 37125304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland.
    Ward T; Brown T; Lewis RD; Kliess MK; de Arellano AR; Quinn CM
    Pharmacoecon Open; 2022 Sep; 6(5):757-771. PubMed ID: 35925491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperkalaemia in Heart Failure.
    Ismail U; Sidhu K; Zieroth S
    Card Fail Rev; 2021 Mar; 7():e10. PubMed ID: 34094588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patiromer: A Review in Hyperkalaemia.
    Blair HA
    Clin Drug Investig; 2018 Aug; 38(8):785-794. PubMed ID: 30030701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life.
    Esteban-Fernández A; Ortiz Cortés C; López-Fernández S; Recio Mayoral A; Camacho Jurado FJ; Gómez Otero I; Molina M; Almenar Bonet L; López-Vilella R
    ESC Heart Fail; 2022 Oct; 9(5):3071-3078. PubMed ID: 35748119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
    Pitt B; Bakris GL; Bushinsky DA; Garza D; Mayo MR; Stasiv Y; Christ-Schmidt H; Berman L; Weir MR
    Eur J Heart Fail; 2015 Oct; 17(10):1057-65. PubMed ID: 26459796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.
    Pitt B; Bushinsky DA; Kitzman DW; Ruschitzka F; Metra M; Filippatos G; Rossignol P; Du Mond C; Garza D; Berman L; Lainscak M;
    ESC Heart Fail; 2018 Jun; 5(3):257-266. PubMed ID: 29369537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can patiromer allow for intensified renin-angiotensin-aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD.
    Mårup FH; Peters CD; Christensen JH; Birn H
    BMJ Open; 2022 Feb; 12(2):e057503. PubMed ID: 35190442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease.
    Rossignol P; Silva-Cardoso J; Kosiborod MN; Brandenburg V; Cleland JG; Hadimeri H; Hullin R; Makela S; Mörtl D; Paoletti E; Pollock C; Vogt L; Jadoul M; Butler J
    Pharmacol Res; 2022 Aug; 182():106277. PubMed ID: 35662631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
    Butler J; Anker SD; Lund LH; Coats AJS; Filippatos G; Siddiqi TJ; Friede T; Fabien V; Kosiborod M; Metra M; Piña IL; Pinto F; Rossignol P; van der Meer P; Bahit C; Belohlavek J; Böhm M; Brugts JJ; Cleland JGF; Ezekowitz J; Bayes-Genis A; Gotsman I; Goudev A; Khintibidze I; Lindenfeld J; Mentz RJ; Merkely B; Montes EC; Mullens W; Nicolau JC; Parkhomenko A; Ponikowski P; Seferovic PM; Senni M; Shlyakhto E; Cohen-Solal A; Szecsödy P; Jensen K; Dorigotti F; Weir MR; Pitt B
    Eur Heart J; 2022 Nov; 43(41):4362-4373. PubMed ID: 35900838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
    Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
    Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of sodium zirconium cyclosilicate for up-titration of renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure: a case series.
    Williams R; James A; Ashton M; Vaughan S; Wong A
    Eur Heart J Case Rep; 2021 Aug; 5(8):ytab281. PubMed ID: 34409249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia: DIAMOND Subanalysis.
    Coats AJS; Anker SD; Lund LH; Filippatos G; Rossignol P; Pitt B; Weir MR; Kosiborod MN; Metra M; Böhm M; Ezekowitz JA; Bayes-Genis A; Mentz RJ; Ponikowski P; Senni M; Cleland JGF; Goudev A; Khintibidze I; Lindenfeld J; Merkely B; Waechter S; Budden J; Perrin A; Butler J
    JACC Heart Fail; 2024 Sep; ():. PubMed ID: 39340493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.
    Anker SD; Kosiborod M; Zannad F; Piña IL; McCullough PA; Filippatos G; van der Meer P; Ponikowski P; Rasmussen HS; Lavin PT; Singh B; Yang A; Deedwania P
    Eur J Heart Fail; 2015 Oct; 17(10):1050-6. PubMed ID: 26011677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure.
    Tardif JC; Rouleau J; Chertow GM; Al-Shurbaji A; Lisovskaja V; Gustavson S; Zhao Y; Bouabdallaoui N; Desai AS; Chernyavskiy A; Evsina M; Merkely B; McMurray JJV; Pfeffer MA
    ESC Heart Fail; 2023 Apr; 10(2):1066-1076. PubMed ID: 36564955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.